SLC7A11 and neoplasm: Spearman correlation analysis exhibited a significant positive correlation between SLC7A11 and PD-L1 expression (p = 0.001, Spearman = 0.18), indicating that SLC7A11 may be a predictive biomarker for tumor immune checkpoint inhibitors (ICIs) therapy (Figure 6C).